EUCTR2004-000607-17-DK进行中（未招募）不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma -
Seattle Genetics, Inc.0 个研究点目标入组 40 人开始时间: 2004年8月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients must have refractory or recurrent HD or refractory or recurrent ALCL.
- •2.Patients must have histologically confirmed CD30+ HD or ALCL. ALK status must be known and tissue must be available for central review. Immunohistochemistry or flow cytometry may be performed on either original diagnostic biopsy material or biopsy tissue of relapsed disease.
- •3.Patients must have bidimensional measurable disease on physical examination or radiologic evaluation.
- •4.Patients must have failed systemic chemotherapy either as initial therapy for advanced disease or as salvage therapy after initial radiotherapy for early stage disease.
- •5.Patients may have received no more than four treatments (radiation, chemotherapy, and/or biologics) prior to enrollment.
- •6.Patients may have received no more than one stem cell transplanta (SCT).
- •Patients who have not had a SCT must be considered ineligible or refuse treatment by SCT when it is available as a treatment option. Treatments associated with bone marrow transplant, such as mobilization and conditioning, will be considered as one regimen.
- •7.Patients must have completed radiotherapy and/or chemotherapy at least four weeks prior to enrollment. Any prior treatment with nitrogen mustard agents, melphalan, or BCNU must have been completed at least six weeks prior to enrollment.
- •8.Patients must have an ECOG performance status of = 2 (see Appendix B) and a life expectancy = three months.
- •9.Patients must be at least 18 years of age.
- •10.Patients must be available for periodic blood sampling, study-related assessments, and management of toxicity at the treating institution.
- •11.Females of childbearing potential must have a negative ß-HCG pregnancy test result within three days of enrollment. All patients must agree to use an effective contraceptive method during the course of the study.
- •12.Patients must give written informed consent. A copy of the signed informed consent form will be retained in the patient’s chart.
- •13.Required baseline laboratory data (Support with GF and/or transfusions is allowed):
- •- Absolute neutrophil count = 1,000/mm3
- •- Platelet count = 50,000/mm3
- •- Serum bilirubin = 1.5 times ULN
- •- Serum creatinine = 1.5 times ULN
- •- Urea BUN = 1.5 times ULN
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with primary cutaneous ALCL, unless they have systemic involvement.
- •2.Patients who have been treated previously with any anti-CD30 antibody
- •3.Patients receiving any investigational biological agent within eight weeks of enrollment or any other investigational agent within four weeks of enrollment
- •4.Patients with a known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation
- •5.Patients with a history of other malignancies during the past five years with the exception of adequately treated basal or squamous cell skin cancer or cervical carcinoma in situ.
- •6.Patients with known systemic viral, bacterial, or systemic fungal infection; patients who are known to be HIV, Hepatitis B antigen positive, or Hepatitis C positive.
- •7.Patients with symptomatic cardiac disease including ventricular dysfunction, coronary artery disease, or arrhythmias, if this would, in the opinion of the investigator interfere with assessment of the safety or efficacy of the study drug.
- •8.Patients with symptomatic brain metastases requiring treatment
- •9.Patients who are pregnant or breastfeeding
- •10.Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment
- •11.Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent
研究者
相似试验
进行中（未招募）
不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma -EUCTR2004-000607-17-BESeattle Genetics, Inc.80
进行中（未招募）
不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma -Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma MedDRA version 6.0PT=Hodgkin's Disease NOS recurrent=10020256PT=Hodgkin's Disease NOS refractory=10020257PT=Anaplastic large cell lymphoma T- and null-cell types recurrent=1002229PT=Anaplastic large cell lymphoma T- and null-cell types refractory=1002230MedDRA version: 6.0Level: PTClassification code 10020256EUCTR2004-000607-17-SESeattle Genetics, Inc.80
进行中（未招募）
不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkins Disease or Anaplastic Large Cell Lymphoma, protocollo SG030-0003Refractory of Recurrent Hodgkin's Disease Anaplastic Large Cell LymphomaLevel: HLGTClassification code 10025319EUCTR2004-000607-17-ITSEATTLE GENETICS INC.
进行中（未招募）
不适用
A phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkin s Disease or Anaplstic Large Cell LymphomaPatients with Refractory or Recurrent Hodgkin s Disease or Anaplastic Large Cell LymphomaMedDRA version: 6.1Level: HLGTClassification code 10025319EUCTR2005-003369-17-ITISTITUTO NAZIONALE PER LA CURA TUMORI80
已完成
1 期
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesHodgkin DiseaseLymphoma, Large-CellSarcoma, KaposiLymphoma, T-Cell, CutaneousLymphoma, B-CellNCT00051597Seagen Inc.70